Imiquimod use in the treatment of lentigo maligna - 07/08/11
Doi : 10.1016/j.jaad.2009.08.023
Jacqueline M. Junkins-Hopkins, MD ⁎ 
Based on the dialogue “Imiquimod for the treatment of melanoma” between M. Shane Chapman, MD, and Stuart Brown, MD
Division of Dermatopathology and Oral Pathology, Department of Dermatology, Johns Hopkins Medical Institutions, Baltimore, Maryland
Reprint requests: Jacqueline M. Junkins-Hopkins, MD, Division of Dermatopathology and Oral Pathology, Department of Dermatology, Johns Hopkins Medical Institution, 600 N Wolfe St, Blalock Bldg, Rm #907, Baltimore, MD 21287.Abstract |
Dialogues in Dermatology, a monthly audio program from the American Academy of Dermatology, contains discussions between dermatologists on timely topics. Commentaries from Dialogues Editor-in-Chief Jacqueline M. Junkins-Hopkins, MD, are provided after each discussion as a topic summary and are provided here as a special service to readers of the Journal of the American Academy of Dermatology.
Le texte complet de cet article est disponible en PDF.| The statements and opinions expressed in this commentary are those of the Editor-in-Chief of Dialogues in Dermatology. |
|
| Funding sources: None. |
|
| Conflicts of interest: Dr Chapman is supported by 3M with grants and is a consultant with Graceway. Dr Brown is a speaker for and received honoraria from Dermik, Galderma, Novartis, and Stiefel. Dr Junkins-Hopkins declared no conflicts of interest. |
© 2009
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 61 - N° 5
P. 865-867 - novembre 2009 Retour au numéro
Article précédent
- Deep cutaneous fungal infections in immunocompromised children
- Danielle Marcoux, Fatemeh Jafarian, Valérie Joncas, Chantal Buteau, Victor Kokta, Albert Moghrabi
- Special Notice Regarding Case Reports
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?